The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abnormal B‐cell cytokine responses a trigger of T‐cell–mediated disease in MS?
Abstract
Objective: To study antibody‐independent contributions of B cells to inflammatory disease activity, and the immune consequences of B‐cell depletion with rituximab, in patients with multiple sclerosis (MS). Methods: B‐Cell effector‐cytokine responses were compared between MS patients and matched controls using a 3‐signal model of activation. The effects of B‐cell depletion on Th1/Th17 CD4 and CD8 T‐cell responses in MS patients were assessed both ex vivo and in vivo, together with pharmacokinetic/pharmacodynamic studies as part of 2 rituximab clinical trials in relapsing–remitting MS. Results: B Cells of MS patients exhibited aberrant proinflammatory cytokine responses, including increased lymphotoxin (LT):interleukin‐10 ratios and exaggerated LT and tumor necrosis factor (TNF)‐α secretion, when activated in the context of the pathogen‐associated TLR9‐ligand CpG‐DNA, or the Th1 cytokine interferon‐γ, respectively. B‐Cell depletion, both ex vivo and in vivo, resulted in significantly diminished proinflammatory (Th1 and Th17) responses of both CD4 and CD8 T cells. Soluble products from activated B cells of untreated MS patients reconstituted the diminished T‐cell responses observed following in vivo B‐cell depletion in the same patients, and this effect appeared to be largely mediated by B‐cell LT and TNFα. Interpretation: We propose that episodic triggering of abnormal B‐cell cytokine responses mediates ‘bystander activation’ of disease‐relevant proinflammatory T cells, resulting in new relapsing MS disease activity. Our findings point to a plausible mechanism for the long‐recognized association between infections and new MS relapses, and provide novel insights into B‐cell roles in both health and disease, and into mechanisms contributing to therapeutic effects of B‐cell depletion in human autoimmune diseases, including MS. ANN NEUROL 2010;67:452–461
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Self-citationMultiple Sclerosis — The Plaque and Its Pathogenesis
Frohman, E. M., Racke, M. K., & Raine, C. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052130 · Cited by 1,740
B cells regulate autoimmunity by provision of IL-10
Fillatreau, S., Sweenie, C. H., McGeachy, M. J., Gray, D., & Anderton, S. M. (2002) · Nature Immunology · doi:10.1038/ni833 · Cited by 1,647
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Frischer, J. M., Bramow, S., Dal-Bianco, A., Lucchinetti, C. F., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., & Lassmann, H. (2009) · Brain · doi:10.1093/brain/awp070 · Cited by 1,450
Mizoguchi, A., Mizoguchi, E., Takedatsu, H., Blumberg, R. S., & Bhan, A. K. (2002) · Immunity · doi:10.1016/s1074-7613(02)00274-1 · Cited by 978
Prevention of Arthritis by Interleukin 10–producing B Cells
Mauri, C., Gray, D., Mushtaq, N., & Londei, M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021293 · Cited by 860
Molecular Mimicry, Bystander Activation, or Viral Persistence: Infections and Autoimmune Disease
Fujinami, R. S., von Herrath, M. G., Christen, U., & Whitton, J. L. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.1.80-94.2006 · Cited by 679
Duddy, M., Niino, M., Adatia, F., Hebert, S., Freedman, M., Atkins, H., Kim, H. J., & Bar-Or, A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.10.6092 · Cited by 653
Self-citationNovel Suppressive Function of Transitional 2 B Cells in Experimental Arthritis
Evans, J. G., Chavez-Rueda, K. A., Eddaoudi, A., Meyer-Bahlburg, A., Rawlings, D. J., Ehrenstein, M. R., & Mauri, C. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.12.7868 · Cited by 570
Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial
Bar‐Or, A., Calabresi, P. A. J., Arnold, D., Markowitz, C., Shafer, S., Kasper, L. H., Waubant, E., Gazda, S., Fox, R. J., Panzara, M., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21363 · Cited by 527
Self-citationRituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients
Cross, A. H., Stark, J. L., Lauber, J., Ramsbottom, M. J., & Lyons, J.-A. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.06.029 · Cited by 454
TLR-Activated B Cells Suppress T Cell-Mediated Autoimmunity
Lampropoulou, V., Hoehlig, K., Roch, T., Neves, P., Gómez, E. C., Sweenie, C. H., Hao, Y., Freitas, A. A., Steinhoff, U., Anderton, S. M., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4763 · Cited by 436 · cited 1×
“In recent years, the ‘2-signal’ model of normal human B-cell activation (involving BCR and CD40 engagement) has been extended to include ‘3rd signals’ that can modulate B-cell responses.(18,21,25,27,32) In relation to B-cell effector cytokine production, we previously reported that upon standard 2-signal activation, B…”
BackgroundToll‐like receptor stimulation as a third signal required for activation of human naive B cells
Ruprecht, C. R., & Lanzavecchia, A. (2006) · European Journal of Immunology · doi:10.1002/eji.200535744 · Cited by 436
Mechanisms for the induction of autoimmunity by infectious agents
Wucherpfennig, K. W. (2001) · Journal of Clinical Investigation · doi:10.1172/jci14235 · Cited by 435
Distinct Profiles of Human B Cell Effector Cytokines: A Role in Immune Regulation?
Duddy, M. E., Alter, A., & Bar-Or, A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.6.3422 · Cited by 369
Self-citationSites and Stages of Autoreactive B Cell Activation and Regulation
Shlomchik, M. J. (2008) · Immunity · doi:10.1016/j.immuni.2007.12.004 · Cited by 312
Helminth infections associated with multiple sclerosis induce regulatory B cells
Correale, J., Farez, M., & Razzitte, G. (2008) · Annals of Neurology · doi:10.1002/ana.21438 · Cited by 311
Infectious causes of multiple sclerosis
Giovannoni, G., Cutter, G. R., Lunemann, J., Martin, R., Münz, C., Sriram, S., Steiner, I., Hammerschlag, M. R., & Gaydos, C. A. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70577-4 · Cited by 295
Not always the bad guys: B cells as regulators of autoimmune pathology
Fillatreau, S., Gray, D., & Anderton, S. M. (2008) · Nature Reviews Immunology · doi:10.1038/nri2315 · Cited by 295
B cells and multiple sclerosis
Franciotta, D., Salvetti, M., Lolli, F., Serafini, B., & Aloisi, F. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70192-3 · Cited by 287
Chaturvedi, A., Dorward, D., & Pierce, S. K. (2008) · Immunity · doi:10.1016/j.immuni.2008.03.019 · Cited by 272
The risk of relapses in multiple sclerosis during systemic infections
Correale, J., Fiol, M., & Gilmore, W. (2006) · Neurology · doi:10.1212/01.wnl.0000233834.09743.3b · Cited by 256
Capolunghi, F., Cascioli, S., Giorda, E., Rosado, M. M., Plebani, A., Auriti, C., Seganti, G., Zuntini, R., Ferrari, S., Cagliuso, M., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.2.800 · Cited by 246
Herlands, R. A., Christensen, S. R., Sweet, R. A., Hershberg, U., & Shlomchik, M. J. (2008) · Immunity · doi:10.1016/j.immuni.2008.06.009 · Cited by 214
Kim, H. J., Ifergan, I., Antel, J. P., Seguin, R., Duddy, M., Lapierre, Y., Jalili, F., & Bar-Or, A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.11.7144 · Cited by 200
Self-citationAntibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid
Owens, G. P., Bennett, J. L., Lassmann, H., O'Connor, K. C., Ritchie, A. M., Shearer, A., Lam, C., Yu, X., Birlea, M., DuPree, C., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21641 · Cited by 188
Regulatory Roles for Cytokine- Producing B Cells in Infection and Autoimmune Disease
Lund, F. E., Garvy, B. A., Randall, T. D., & Harris, D. P. (2004) · Current Directions in Autoimmunity · doi:10.1159/000082086 · Cited by 181
Infectious causes of multiple sclerosis
GILDEN, D. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70023-5 · Cited by 174
McLaughlin, K. A., & Wucherpfennig, K. W. (2008) · Advances in immunology · doi:10.1016/s0065-2776(08)00404-5 · Cited by 110
von Büdingen, H. ‐., Harrer, M. D., Kuenzle, S., Meier, M., & Goebels, N. (2008) · European Journal of Immunology · doi:10.1002/eji.200737784 · Cited by 98
Neuropathobiology of multiple sclerosis
Peterson, J. W., & Trapp, B. D. (2005) · Neurologic Clinics · doi:10.1016/j.ncl.2004.09.008 · Cited by 97
Autoreactive B Cells Discriminate CpG-Rich and CpG-Poor DNA and This Response Is Modulated by IFN-α
Uccellini, M. B., Busconi, L., Green, N. M., Busto, P., Christensen, S. R., Shlomchik, M. J., Marshak‐Rothstein, A., & Viglianti, G. A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.9.5875 · Cited by 89
The Immunology of Multiple Sclerosis
Bar-Or, A. (2008) · Seminars in neurology · doi:10.1055/s-2007-1019124 · Cited by 78
Self-citationDuda, P. W., Krieger, J. I., Schmied, M. C., Balentine, C., & Hafler, D. A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.12.7300 · Cited by 68
The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies
Racke, M. K. (2008) · Current Opinion in Neurology · doi:10.1097/01.wco.0000313359.61176.15 · Cited by 65
Activated B cells in autoimmune diseases: the case for a regulatory role
Anderton, S. M., & Fillatreau, S. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0950 · Cited by 61
Petereit, H.-F., Moeller‐Hartmann, W., Reske, D., & RUBBERT, A. (2007) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2007.00958.x · Cited by 59
Cepok, S., von Geldern, G., Grummel, V., Hochgesand, S., Celik, H., Hartung, H., & Hemmer, B. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.06.031 · Cited by 59
B-cell-derived interleukin-10 in autoimmune disease: regulating the regulators
Rieger, A. M., & Bar‐Or, A. (2008) · Nature reviews. Immunology · doi:10.1038/nri2315-c1 · Cited by 50
Self-citationGray matter pathology and multiple sclerosis
Wegner, C., & Stadelmann, C. (2009) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-009-0058-x · Cited by 25
Cross, A. H., & Stark, J. L. (2005) · Immunologic Research · doi:10.1385/ir:32:1-3:085 · Cited by 23
Cited by
Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
Self-citationvon Büdingen, H.-C., Palanichamy, A., Lehmann-Horn, K., Michel, B. A., & Zamvil, S. S. (2015) · European Neurology · doi:10.1159/000377675 · Cited by 1,463
Kappos, L., Li, D., Calabresi, P. A., O'Connor, P., Bar-Or, A., Barkhof, F., Yin, M., Leppert, D., Glanzman, R., Tinbergen, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61649-8 · Cited by 743
Self-citationB cell depletion therapies in autoimmune disease: advances and mechanistic insights
Lee, D. S. W., Rojas, O. L., & Gommerman, J. L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00092-2 · Cited by 658
B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells
Barr, T. A., Shen, P., Brown, S., Lampropoulou, V., Roch, T., Lawrie, S., Fan, B., O’Connor, R. A., Anderton, S. M., Bar-Or, A., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111675 · Cited by 649
Self-citation
Metadata
- Authors
- Bar‐Or, A., Fawaz, L., Fan, B., Darlington, P. J., Rieger, A., Ghorayeb, C., Calabresi, P. A., Waubant, E., Hauser, S. L., Zhang, J., & Smith, C. H.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2010-04
- Volume
- 67
- Issue
- 4
- Pages
- 452-461
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1981621288
- Cited by
- 521
- References
- 42
- FWCI
- 12.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.